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Serum nonesterified fatty acids, ghrelin, and homocysteine
levels in women with polycystic ovary syndrome
İsmail TEMEL1, Önder ÇELİK2, Şeyma HASÇALIK2, Nilüfer ÇELİK3, İbrahim ŞAHİN4, Süleyman AYDIN5

Aim: To investigate the possible relationship of serum levels of nonesterified fatty acids (NEFA), ghrelin, and
homocysteine levels to metabolic and hormonal features in women with polycystic ovary syndrome (PCOS).
Materials and methods: Thirty women with PCOS and 30 healthy women with similar age and body mass index (BMI)
were recruited. Fasting serum NEFA, ghrelin, homocysteine, growth hormone (GH), cardiac troponin I, glucose, insulin,
lipids, and homeostasis model assessment of insulin resistance (HOMA-IR) were measured.
Results: Serum NEFA, homocysteine, insulin, HOMA-IR, cholesterol, and testosterone levels were significantly higher
but in contrast ghrelin level was significantly lower in women with PCOS compared to the controls. No significant
differences were found in the troponin I and GH levels between the 2 groups. Significant positive correlations between
insulin-NEFA and insulin-homocysteine levels were observed. There was no significant correlation between ghrelininsulin and ghrelin-homocysteine levels.
Conclusion: The decreased ghrelin, elevated NEFA and homocysteine levels, and the correlation of NEFA and
homocysteine to fasting insulin level might play an important role in the pathogenesis of the PCOS. These findings need
to be confirmed and larger prospective and controlled studies are necessary.
Key words: NEFA, ghrelin, homocysteine, insulin, PCOS

Polikistik over sendromlu kadınlarda serum nonesterifiye yağ asitleri, grelin ve
homosistein düzeyleri
Amaç: Nonesterifiye yağ asitleri (NEFA), grelin ve homosistein serum düzeyleri ile polikistik over sendromlu (PCOS)
kadınların metabolik ve hormonal özellikleri arasındaki ilişkileri araştırmak.
Yöntem ve gereç: PCOS’lu 30 kadın ile benzer yaş ve vucut kitle indeksi (BMI) ne sahip sağlıklı 30 kadın çalışmaya dahil
edildi. Açlık serum NEFA, grelin, homosistein, büyüme hormonu (GH), kardiyak troponin I, glukoz, insülin, lipitler ve
homeostasis model assessment-insülin direnci (HOMA-IR) testleri çalışıldı.
Bulgular: Kontrole kıyasla PCOS’lu kadınlarda serum NEFA, homosistein, insulin, HOMA-IR, kolesterol ve testosteron
düzeyleri önemli oranda yüksek fakat grelin seviyesi düşük bulundu. Gruplar arasında troponin I ve GH düzeyleri
yönünden fark bulunamadı. İnsülin-NEFA ve insülin-homosistein düzeyleri arasında istatiksel anlamlı ve pozitif
korelasyon saptanırken, grelin-insülin ve grelin-homosistein parametreleri arasında anlamlı bir korelasayon saptanmadı.
Sonuç: Azalmış grelin, yüksek NEFA ve homosistein düzeyleri; açlık insülin düzeyleri ile NEFA ve homosistein düzeyleri
arasındaki korelasyonlar PCOS patogenezinde önemli rol oynayabilir. Bu sonuçlar daha büyük prospektif ve kontrollü
çalışmalar ile konfirme edilmelidir.
Anahtar sözcükler: NEFA, grelin, homosistein, insülin, PCOS
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Introduction
Polycystic ovary syndrome (PCOS) is one of the
most common endocrine diseases affecting almost
10% of women in the reproductive age (1). Despite
the ambiguity of the etiology of PCOS to date, several
studies have suggested that insulin resistance (IR)
plays an important role in the pathogenesis of the
syndrome (2,3). IR is defined as the reduced reaction
to normal circulating level of insulin that may be a
major risk factor for occurrence of cardiovascular
disease (CVD) in women with PCOS (4).
IR in fat cells reduces the effects of insulin and
results in elevation of hydrolysis of stored triglycerides
(5). The increase of mobility of stored lipids in these
cells elevates nonesterified fatty acids (NEFA) in the
blood plasma (5,6). Physiological elevations in plasma
NEFA concentrations inhibit insulin stimulated
peripheral glucose uptake in a dose-dependent
manner (6). It is now known that NEFA interfere with
insulin signaling in skeletal muscle at the level of IRS1 serine phosphorylation (7).
Ghrelin, a 28-amino acid peptide recently isolated
from rat and human stomach, is the long-searched
natural ligand for the GH secretagogue receptor (8). It
is associated with energy balance, obesity, IR, and
gonadal function. Hypothalamic areas are the major
binding sites of ghrelin (9). The available information
on ghrelin level in women with PCOS is rather
conflicting: some studies reported a reduction (10),
some conversely reported elevation (11) of
concentrations and some others reported no
significant differences between women with PCOS
and normal ovulatory women (12).
Homocysteine, a sulfur-containing amino acid
formed during the metabolism of methionine, is toxic
to vascular endothelium (13). PCOS has been
associated with the elevated plasma homocysteine and
correlated to IR (14). Higher homocysteine level has
been observed in the hyperinsulinemic subjects and
so it has been suggested that homocysteine could have
a great role in risk factors of CVD in PCOS (13,15).
The
available
information
on
serum
homocysteine, ghrelin, and NEFA levels in women
with PCOS are also conflicting, as well as the number
of subjects involved in most of studies is relatively
small (5,11,12,14). From this perspective the present
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study was designed to assess the possible relationship
of NEFA, homocysteine, and ghrelin to metabolic and
hormonal features in women with PCOS, employing
a substantial number of subjects.
Materials and methods
Thirty women diagnosed with PCOS and 30
healthy female with no known medication or
menstrual disorders having similar age and BMI were
included in this study. PCOS was documented when
at least 2 of the following 3 features were present after
the exclusion of other etiologies (Rotterdam criteria):
oligo/amenorrhea (fewer than 6 menstrual periods in
the preceding year); clinical (Ferriman–Gallwey score
> 8) and/or biochemical signs of hyperandrogenism
and ultrasonographic findings (16). The ultrasound
criteria used for diagnosis of PCOS were the presence
of 12 or more follicles in each ovary measuring 2–9
mm in diameter, and/or increase of ovarian volume
(>10 mL). The PCOS subjects were selected from a
group of PCOS patients who were seeking treatment
for menstrual irregularity, acne, hirsutism or
infertility, and the controls were selected from general
community. Clinical hyperandrogenism was
quantified by the Ferriman–Gallwey scoring system.
Hirsutismus scores on each body area were made by
2 experienced physicians.
None of the subjects had medication for at least 6
months prior to the study. None of the studied
individuals were undergoing caloric restrictions at the
time of the study or doing physical exercise. Their
height and weight and waist circumferences were
measured. The waist circumference of subjects was
measured in standing position by placing a soft tape
measure midway between the lowest rib and the iliac
crest. All other measurements were performed when
the patients were in a standing position with joined
feet, relaxed abdomen, and arms at their sides. BMI
was measured as the ratio of the weight to the square
of the height. Blood pressure was measured on the
right arm, with the subjects in a sitting position and
relaxed.
The blood of the subjects was sampled in the
morning following an overnight fast during early
follicular phase (days 2–5) of, spontaneous or
progesterone induced, withdrawal bleeding. The blood
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samples were centrifuged and then serum or plasma
aliquots were frozen at -20 °C until assayed. Patients
having type-2 diabetes, thyroid, or renal, liver, or
cardiovascular dysfunctions as well as Cushing’s
syndrome, hyperprolactinemia, androgen-secreting
tumors, and late-onset 21-hydroxylase deficiency were
excluded from the study. In all patients a-basal
hormonal evaluation by means of GH, FSH, LH,
estradiol, testosterone, dehydroepiandrosterone sulfate
(DHEA-S), sex-hormone-binding globulin (SHBG),
and b-metabolic evaluation by means of concentration
of NEFA, ghrelin, homocysteine, cardiac troponin I
(cTnI), glucose and insulin, was carried out. The study
was performed according to the guidelines of the
Helsinki Declaration on human experimentation and
was approved by the local ethics committee.
Biochemical studies
In all subjects, fasting serum NEFA concentrations
were determined using an enzymatic-colorimetric
method with the Wako NEFA C test kit (Wako, Neuss,
Germany). Fasting serum total homocysteine levels
were determined with an enzyme immunoassay kit
(Axis-Shield, Oslo, Norway). Total ghrelin (Linco
Research, Missouri, USA) levels were measured by
radioimmunoassay with a gamma counter (LKB
WALLAC, 1261 Multigamma, Gamma Counter,
Turku, Finland). Serum cTnI concentrations were
measured by a commercial cTnI kit using a
chemiluminescent enzyme immunoassay method
(Pathfast™ cTnI, Compact immuno-analyzer,
Mitsubishi Kagaku Iatron, Inc., Tokyo, Japan). The
respective inter- and intra-assay coefficients of
variation (CV) of these parameters were 5.1% and
3.8% for NEFA; 4.8% and 3.2% for homocysteine;
14.8% and 10.1% for total ghrelin; 4.1% and 3.7% for
cTnI.
Serum FSH, LH, estradiol (E2), total testosterone,
SHBG, GH, insulin, and DHEAS levels were
measured by competitive chemiluminescent enzyme
immunoassay method using the kits with the same
brand (Immulite 2000 Analyzer, Diagnostic Products
Corporation; DPC, Los Angeles, CA, USA). The
respective inter- and intra-assay CV were 7.3% and
5.5% for FSH; 7.6% and 5.0% for LH; 6.6% and 5.1%
for E2; 8.3% and 6.2% for total testosterone; 7.0% and
5.2% for SHBG; 6.8% and 5.2% for GH; 5.7% and
4.3% for insulin; 5.3% and 3.9% for DHEAS.

Fasting glucose, triglycerides (TG), total
cholesterol (TC), and high-density lipoprotein
cholesterol (HDL-C) concentrations were measured
by enzymatic colorimetric assay methods using an
Olympus AU 2700 autoanalyser (Olympus Optical
Co. Ltd., Japan) and commercially available kits
(Olympus Diagnostica GmbH, WendenstraBe,
Hamburg, Germany). The respective inter- and intraassay CV were 3.4% and 3.0% for fasting glucose; 3.2%
and 2.7% for TGs; 2.7% and 2.4% for TC; 11.6% and
8.1% for HDL-C. Low-density lipoprotein cholesterol
(LDL-C) concentrations were calculated using
Friedewald formula (17): LDL-C = TC - HDL-C –
TG/5, and IR was calculated using the homeostasis
model assessment insulin resistance index (HOMAIR) (18), given as: HOMA-IR = fasting insulin
(mU/mL) × fasting glucose (mg/dL) /405.
Statistical analysis
The Statistical Package for the Social Sciences,
version 11.0 (SPSS Inc., Chicago, IL, USA) was used
for statistical analysis. The normality of continuous
variables in groups was tested by the Shapiro Wilk
test. Since the variables did not show a normal
distribution Mann-Whitney U-test was used for
comparison. Bivariate correlations (computing
Pearson’s coefficient with their significance levels)
between NEFA, ghrelin, homocysteine, GH, cTnI, and
other variables in PCOS and control patients were
calculated. The data are presented in mean ± SD. For
all comparisons, the statistical significance was
defined as P < 0.05.
Results
The results manifested through this particular
work are shown in Table 1. From basal conditions
point of view there were no significant differences
between the 2 groups in terms of age and
anthropometric parameters, confirming that the 2
cohorts are comparable. However as compared to the
healthy control subjects, PCOS patients had
significantly higher NEFA, homocysteine, fasting
insulin, HOMA-IR, LH and testosterone levels, but
lower serum ghrelin, E2, and SHBG levels. In terms
of cTnI and GH, the 2 groups were comparable. Also
the M-Ferriman-Gallwey score was found as
significantly higher in women with PCOS compared
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Table 1. Comparison of anthropometric data, and hormonal and biochemical parameters (mean
± SD) between PCOS and control groups.
Characteristic

PCOS
(n = 30)

Control
(n = 30)

P
value*

Age (yr)

23.13 ± 4.28

23.30 ± 2.76

0.581

Weight (kg)

58.91 ± 11.9

53.56 ± 5.63

0.076

2

BMI (kg/m )

22.31 ± 5.04

20.77 ± 2.08

0.505

Waist circumference (cm)

71.95 ± 11.7

68.40 ± 5.01

0.514

NEFA (mg/dL)

6.93 ± 3.51

4.36 ± 2.52

0.002

Homocysteine (μmol/L)

16.25 ± 6.76

8.91 ± 6.47

<0.001

cTnI (ng/mL)

0.002 ± 0.004

0.002 ± 0.005

0.074

Ghrelin (pg/mL)

815 ± 323

1459 ± 306

<0.001

FSH (mIU/mL)

5.94 ± 1.70

5.90 ± 1.63

0.802

LH (mIU/mL )

8.63 ± 4.47

5.63 ± 3.16

0.013

E2 (pg/mL)

41.85 ± 16.5

112.58 ± 87.3

<0.001

T-testosterone (ng/dL)

62.95 ± 25.2

45.95 ± 18.0

0.005

SHBG (nmol/mL)

44.53 ± 42.9

54.03 ± 17.2

<0.001

GH (ng/mL)

1.49 ± 2.24

1.83 ± 3.14

0.988

Fasting insulin (mU/mL)

19.69 ± 12.64

11.99 ± 5.69

0.004

DHEA-S (μg/dL)

215.96 ± 81.4

258.16 ± 98.5

0.110

Fasting glucose (mg/dL)

90.73 ± 11.0

90.93 ± 14.0

0.615

TG (mg/dL)

99.63 ± 50.6

110.23 ± 38.7

0.117

TC (mg/dL)

156.86 ± 35.8

168.23 ± 32.3

0.119

HDL-C (mg/dL)

48.59 ± 14.8

51.43 ± 12.4

0.450

LDL-C (mg/dL)

96.76 ± 25.6

100.29 ± 18.3

0.222

HOMA-IR

4.69 ± 2.87

2.57 ± 1.45

<0.001

M-Ferriman-Gallwey score

15.43 ± 4.98

8.53 ± 2.44

<0.001

*P < 0.05 was considered significant. NEFA: nonesterified fatty acids, HDL-C: high-density
lipoprotein cholesterol, HOMA-IR: homeostasis model assessment insulin resistance index, LDLC: low-density lipoprotein cholesterol, TC: total cholesterol, TG: triglycerides, SHBG: sexhormone-binding globulin, GH: growth hormone, DHEA-S: dehydroepiandrosterone sulfate,
cTnI: cardiac troponin-I

to controls, but there were no distinguishable
differences observed between groups in other
parameters.
From the results it was observed that NEFA has a
positive correlation with GH (r = 0.256, P < 0.05),
fasting serum insulin levels (r = 0.356, P < 0.007;
Figure 1), and HOMA-IR index (r = 0.294, P < 0.05).
Homocysteine level had a positive correlation with
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LH (r = 0.282, P < 0.05) and fasting serum insulin
level (r = 0.545, P < 0.001; Figure 2). Ghrelin level had
a positive correlation with HOMA-IR index (r =
0.364, P < 0.004). Nonetheless, as shown in Figures 3
and 4, there was no significant correlation between
ghrelin-insulin (r = 0.225, P = 0.096) and ghrelinhomocysteine levels (r = 0.253, P = 0.058). GH was
positively correlated with SHBG (r = 0.342, P < 0.01).
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Figure 2. Correlation between serum homocysteine and fasting
insulin levels in women with PCOS.
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Figure 1. Correlation between serum NEFA and fasting insulin
levels in women with PCOS.

ghrelin (pg/mL)

r = 0.545
P < 0.001

30

2000
1800
1600
1400
1200
1000
800
600
400
200
0

r = 0.253
P = 0.058
0

10

20
30
homocysteine (µmol/L)

40

Figure 3. Correlation between serum ghrelin and fasting insulin
levels in women with PCOS.

Figure 4. Correlation between serum ghrelin and homocysteine
levels in women with PCOS.

Discussion

a previous report in which a highly significant positive
correlation between ghrelin concentration and the
degree of IR in PCOS subjects was shown (2). This
interrelationship is in fact not clear enough yet.
However, based on currently available information
(20), it may be speculated that this relationship could
be due to the presence of a moderate to severe IR.
Whether ghrelin participates in the mechanisms
brings about peripheral IR is also unknown because it
is still controversial whether ghrelin stimulates or
inhibits insulin secretion (21,22).

The obtained results, with reference to basic
hormonal profile homocysteine, NEFA and ghrelin
levels in women with PCOS, are in accord with wellestablished evidence on the fundamental
characteristics of PCOS (6;14). In most of the previous
studies (2,19) a reduction in ghrelin concentration in
women with PCOS have been reported, but in some
others (11,12), in contrast, such a reduction has not
been reported. The present study revealed a lower
ghrelin level, which is in line with the majority of the
previous reports (2,19), and significantly higher
serum NEFA and homocysteine levels but comparable
GH and cTnI concentrations in women with PCOS as
compared to the controls.
The detected positive correlation of ghrelin level
to IR in women with PCOS is also in agreement with

From in vivo studies it is known that infusion of
ghrelin decreases insulin secretion (23), which could
be because of the expression of ghrelin in pancreatic
islet-cells, and so exerts a direct inhibitory action on
insulin release (21). Other in vivo and in vitro studies,
in contrast, suggest a stimulatory action of ghrelin on
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insulin release (22). On the other hand, in vivo insulin
has no impact on circulating ghrelin in humans, which
denotes a further complex interplay between both
hormones (24). In the PCOS patients involved in the
present study, ghrelin did not correlate with insulin and
homocysteine, which agrees with a simple mechanism
explaining the decrease in serum ghrelin in insulinresistant PCOS subjects. This could suggest a weak link
between ghrelin, fasting insulin, and homocysteine
concentrations, and show that the dysregulated
ghrelin-homocysteine system in women with insulinresistant PCOS might be a cause of risk of CVD.
Ghrelin concentration has been reported to have
a negative correlation with body mass index (BMI),
and in turn with the obesity that increases in response
to weight loss (12,20), as well as with indices of IR
(11). A negative correlation between circulating
ghrelin and androgen levels was also reported (25). In
the present study, a fractional relation of ghrelin,
NEFA, and homocysteine to BMI was observed but
this was not statistically significant. This discrepancy
might be due to a relatively narrow BMI range in the
subjects involved in the study compared with those
reported by others (20).
It remains unclear whether ghrelin is linked to
insulin sensitivity via an insulin-mediated process or
other mechanisms associated with IR, such as elevated
NEFA. When the regulation of energy supply in
adipose tissue is impaired, the plasma NEFA levels
become elevated due to the increase of mobilization of
stored lipids (5). Excessive NEFA causes ectopic fat
storage and increase of NEFA metabolites in nonadipose tissues (5), which have lipotoxic effects on
skeletal muscle and other tissues (6).
Boden et al. (6) showed an important link in
between NEFA, obesity, IR, and type 2 diabetes such
that the physiological change caused by elevation of
plasma NEFA in most of obese subjects inhibits
insulin-stimulated glucose uptake into muscle. It
seems that the markedly increase of NEFA levels in
women with PCOS manifested in this study closely
related to IR, and this relation is supported by
previous studies reporting the elevation of serum
NEFA levels in PCOS patients, and the suppressive
effect of extreme fat diet on fasting ghrelin levels
(26,27). Our findings also indicated that ghrelin, apart
from its role in the control of appetite and body
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weight, could be linked to IR and possibly
homocysteine levels. However, whether high NEFA
and homocysteine, and low ghrelin levels in PCOS are
a cause or the consequence of IR awaits further
investigation.
The possible determinants of elevation of
homocysteine concentration are still debated among
researchers who found significant correlations between
homocysteine and IR (14) as well as those who did not
observe such correlations (28). Badawy et al. (29)
found a significantly higher homocysteine level among
PCOS women with IR compared to those without IR.
A recent study confirmed the presence of increased
serum homocysteine concentration in obese as well as
in non-obese PCOS women (28). As the 2 groups
involved in our study were compared, the
homocysteine level was significantly higher and there
were positive correlations among serum homocysteine,
insulin, and LH levels in PCOS patients. Although this
appears to be a good outcome demonstrating the role
of IR, but this is not the sole cause of
hyperhomocysteinemia in women with PCOS; this
elevation might be due to the influence of LH.
Hyperhomocysteinemia is associated with
hyperinsulinemia and partly accounts for increase of
risk of CVD associated with IR (30). Meigs et al. (30)
proposed
a
direct
association
between
hyperhomocysteinemia and IR concerning their
similar pathogenetic effects on vascular endothelial
cells, and a modest association between
hyperinsulinemia and fasting levels of plasma
homocysteine. Schachter et al. (14) found a significant
correlation between IR and homocysteine levels
regardless of body weight in women with PCOS. The
high rate of homocysteine observed in the PCOS
subjects suggests that homocysteine may also play a
role in the risks of CVD
In conclusion, significant positive correlations
between insulin-NEFA and insulin-homocysteine
levels as well as between ghrelin-HOMA-IR index
were demonstrated in women with PCOS. As the
elevation of NEFA and homocysteine can be linked to
IR, they in fact may account for the increased risk of
CVD found in insulin-resistant women with PCOS
(13). In spite of these profound metabolic aberrations,
the GH and cTnI levels were not significantly different
between the 2 groups.
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Many studies conducted in this direction support
existence of interactions between ghrelin and
insulin metabolism. The nature of interactions
between ghrelin and homocysteine has not been
clarified yet which could be due to variations in
insulin sensitivity (3). It should be noted that the
close relation of insulin to homocysteine and NEFA
levels, which is observed here, may indicate some

factors other than simple IR. Also one should bear
in mind that PCOS might affect NEFA,
homocysteine, and ghrelin concentrations and cause
miscellany in clinical and biochemical
manifestations. The results from this study suggest
that these findings need to be confirmed and a
larger prospective and controlled study and longterm follow-up are necessary.
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